Updated:
Rosetta Capital
Rosetta Capital is a specialist UK venture firm executing direct secondary transactions in life sciences and medical devices across North America and Europe.
Rosetta Capital
Rosetta Capital is an SEC-registered investment adviser established in Haddenham in 2014. It has been registered since then.
General information
Firm type
Venture Capital
Year founded
2001
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
Haddenham
Corporate office
Rectory House, Haddenham, HP17 8DA, United Kingdom
Additional offices
London, United Kingdom
Principals
Jonathan Hepple
Team
Ken MacLeod
Team
Michael Forer
Team
Matthew James
Team
Donovan Leung
Team
Melissa Riachi
Team
Sector focus
Frequently asked questions
What is Rosetta Capital's core investment strategy?
Rosetta makes direct secondary purchases of venture stakes in life-sciences and medical-device companies. It typically buys positions from investors or corporations that need liquidity, then often participates in follow-on financings to support the portfolio company's next growth stage. The firm concentrates on complex, negotiated transactions rather than auctioned fund interests.
How does Rosetta source its deals?
The firm sources proprietary secondary opportunities from European and North American healthcare investors and corporates looking to divest part or all of an investment. This route makes each transaction bilateral and negotiated, rather than coming through a broad intermediary auction, though Rosetta does not disclose specific sourcing partnerships.
Does Rosetta Capital operate as a single-family office?
No. Rosetta Capital is structured as a specialist venture capital firm, authorized and regulated by the UK Financial Conduct Authority. It is not the private-investment arm of a single family or individual fortune.
Which sectors does Rosetta specifically target for investment?
The firm invests exclusively in the life sciences and medical device sectors. Its portfolio spans biologics, small-molecule therapeutics, drug delivery, specialty pharma and medtech, with disclosed names including Immunocore, Mission Therapeutics and JenaValve.
Does Rosetta participate in fund commitments or only direct deals?
Rosetta's activity is centered on direct secondary transactions in individual companies, not on buying limited-partner fund interests. Public materials do not indicate any separate fund-of-funds or primary LP commitment program.
Where is Rosetta Capital's presence outside the UK?
While its registered offices are in Oxford and London, the firm's investment horizon is global, with a stated track record of executing transactions across North America and Europe. No additional office locations are disclosed.
What is Rosetta Capital's known posture on co-investing alongside external GPs?
The firm makes direct secondary purchases and joins follow-on rounds, placing it alongside existing co-investors and management teams. Rosetta does not market a separate co-investment program for external limited partners, operating instead as a principal investor through its own fund vehicles.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: